Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled

Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled

315842

Pridopidine Arm of HEALEY ALS Platform Trial Fully Enrolled

Prilenia Therapeutics announced the completion of patient enrollment in the pridopidine arm of the HEALEY ALS platform trial, the first study to simultaneously test multiple experimental therapies for amyotrophic lateral sclerosis (ALS). Prilenia’s oral therapy pridopidine was selected as the trial’s fourth regimen (NCT04615923), with 163 ALS patients recruited ahead of schedule at the trial’s 52 U.S. sites since January 2021. “We selected pridopidine to participate in the HEALEY Platform Trial out of approximately 30 investigational treatments…

You must be logged in to read/download the full post.